Domagrozumab is a novel antibody, which is being developed as a treatment for the condition and is currently being tested in phase II clinical trials. It works by impacting myostatin, a naturally occurring protein in muscles that helps control muscle growth. Blocking the activity of myostatin is thought to be a promising treatment option for muscle wasting diseases such as DMD. Domagrozumab is delivered as a monthly intravenous injection, and if licenced, could offer a new mode of treatment for children with DMD.
Domagrozumab (PF-6252616) for Duchenne muscular dystrophy in children and adolescents
